Jubilant Therapeutics appoints Dr. Robert Glassman as a member of the Board of Directors

Bedminster, New Jersey (ots/PRNewswire) – Jubilant Therapeutics Inc., a biopharmaceutical company developing small molecule modulators for unmet medical needs in oncology and autoimmune diseases, today announced the inclusion of Dr. Robert Glassman announced to the company’s board of directors. Dr. Glassman will serve as an independent non-executive director effective February 1, 2021. “Rob’s experience and … Read more

Allergy and asthma are not an obstacle to COVID-19 vaccination

Austrian Society for Pneumology (ÖGP) informs about COVID-19 vaccination for allergy sufferers and asthma patients Vienna (OTS) – Reports of allergic reactions to the two currently available mRNA vaccines against COVID-19 are currently causing uncertainty among allergy sufferers and asthma patients *. Prim. Priv.-Doz. Dr. Fritz Horak from the working group Allergy and asthma of … Read more

Clinical Severity Reduction of COVID-19: Jubilant Therapeutics Announces Research Collaboration with Wistar Institute to Evaluate Novel PAD4 Inhibitor Activity

Bedminster, N.j. (ots/PRNewswire) – Jubilant Therapeutics Inc., a biopharmaceutical company developing small molecule modulators to meet medical needs in oncology and autoimmune diseases, today announced its collaboration with the Wistar Institute, an international leader in biomedical research. The aim is to evaluate the ability of peptidyl arginine deiminase-4 (PAD4) inhibitors, provided by Jubilant Therapeutics, to … Read more

Economy, trade & finance: SHARES IN FOCUS: Online pharmacies on the rise

The electronic prescription Bank of America took on the valuation of the two companies and advised buying both stocks. At the same time, the experts set a price target of 500 francs for the paper of the Swiss company Zur Rose, which is also very active in Germany, and one of 200 euros for the … Read more